Imunon, Inc. Common Stock (IMNN)

Price$3.10

Favorite Metrics

Price vs S&P 500 (26W)-47.48%

Price vs S&P 500 (4W)-1.48%

Market Capitalization$12.36M

All Metrics

Book Value / Share (Quarterly)$2.07

P/TBV (Annual)0.34x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-4.15

Price vs S&P 500 (YTD)-22.77%

Gross Margin (TTM)34.14%

Net Profit Margin (TTM)-6901.92%

EPS (TTM)$-8.57

10-Day Avg Trading Volume0.04M

EPS Excl Extra (TTM)$-8.57

EPS (Annual)$-1.58

ROI (Annual)-447.66%

Gross Margin (Annual)16.33%

Net Profit Margin (5Y Avg)-4275.20%

Cash / Share (Quarterly)$2.57

ROA (Last FY)-195.53%

EBITD / Share (TTM)$-7.13

ROE (5Y Avg)-173.69%

Operating Margin (TTM)-7361.54%

Cash Flow / Share (Annual)$-4.15

P/B Ratio1.75x

P/B Ratio (Quarterly)1.66x

Net Income / Employee (Annual)$-1

EV / Revenue (TTM)6.88x

Net Interest Coverage (TTM)-7.18x

ROA (TTM)-157.02%

EPS Incl Extra (Annual)$-1.58

Current Ratio (Annual)2.32x

Quick Ratio (Quarterly)1.90x

3-Month Avg Trading Volume0.08M

52-Week Price Return-72.40%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$3.94

P/S Ratio (Annual)24.71x

Asset Turnover (Annual)0.01x

52-Week High$41.22

Operating Margin (5Y Avg)-5140.80%

EPS Excl Extra (Annual)$-1.58

CapEx CAGR (5Y)69.59%

Tangible BV CAGR (5Y)51.40%

26-Week Price Return-38.74%

Quick Ratio (Annual)1.90x

13-Week Price Return-15.07%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)2.32x

Enterprise Value$3.576

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-29.83%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)1.35x

Pretax Margin (Annual)-7494.00%

Cash / Share (Annual)$2.57

3-Month Return Std Dev48.66%

Gross Margin (5Y Avg)33.75%

Net Income / Employee (TTM)$-1

ROE (Last FY)-447.66%

Net Interest Coverage (Annual)-4.65x

EPS Basic Excl Extra (Annual)$-1.58

P/FCF (TTM)2.05x

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-8.57

Receivables Turnover (Annual)0.00x

ROI (TTM)-406.72%

P/S Ratio (TTM)23.76x

Pretax Margin (5Y Avg)-4956.80%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$3.94

Price vs S&P 500 (52W)-107.49%

Year-to-Date Return-18.64%

5-Day Price Return4.73%

EPS Normalized (Annual)$-1.58

ROA (5Y Avg)-90.30%

Net Profit Margin (Annual)-7180.00%

Month-to-Date Return5.44%

Cash Flow / Share (TTM)$-3.05

EBITD / Share (Annual)$-1.56

Operating Margin (Annual)-7658.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-163.88%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-8.57

P/TBV (Quarterly)0.34x

P/B Ratio (Annual)1.66x

Inventory Turnover (TTM)2.94x

Pretax Margin (TTM)-7203.85%

Book Value / Share (Annual)$2.07

Price vs S&P 500 (13W)-17.93%

Beta2.16x

P/FCF (Annual)5.47x

Revenue / Share (TTM)$0.00

ROE (TTM)-406.72%

52-Week Low$2.52

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.00

Industry Peers — Pharmaceuticals(308)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
IMNNImunon, Inc. Common Stock	23.76x	—	34.14%	—	$3.10
LLYEli Lilly & Co.	13.45x	44.70%	83.04%	27.59%	$919.90
JNJJohnson & Johnson	5.82x	7.87%	67.95%	14.90%	$230.69
ABBVABBVIE INC.	5.97x	8.57%	71.62%	-2.88%	$203.71
MRKMerck & Co., Inc.	4.51x	1.31%	78.55%	21.23%	$117.10
AZNAstraZeneca PLC	5.39x	8.63%	81.31%	21.88%	$200.69
NVSNovartis AG	4.87x	8.91%	75.82%	15.26%	$150.99
NVONovo-Nordisk A/S	3.74x	6.43%	80.98%	20.66%	$40.46
ABTAbbott Laboratories	3.71x	6.59%	56.50%	8.20%	$96.00
PFEPfizer Inc.	2.50x	-1.64%	75.81%	-3.51%	$27.52
BMYBristol-Myers Squibb Co.	2.52x	-0.22%	72.63%	—	$59.13

About

Imunon Inc is a clinical-stage biotechnology company developing a non-viral DNA platform to treat various human diseases by leveraging the body's natural immune mechanisms. Its lead program, IMNN-001, is a DNA-based immunotherapy for ovarian cancer that has completed Phase II clinical trials. The company is also advancing IMNN-101, a COVID-19 booster vaccine candidate, currently in first-in-human studies.